Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer

2020 Genitourinary Cancers Symposium

Published: 14 Feb 2020

Views: 920

Rating:

Save

Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Pavlos Msaouel speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the combination of sitravatinib and nivolumab for the treatment of advanced clear cell renal cell cancer (aCCRCC) in patients who have progressed on prior VEGF-targeted therapy.

He explains the background of this early phase I/II study, along with the main results achieved in this study.

Dr Msaouel concludes that this combination did to demonstrate any unexpected safety signals and achieved higher objective responses and longer disease control compared to the use of nivolumab alone.

Related Videos

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma

Dr Talal El Zarif - Dana-Farber Cancer Institute, Boston, USA

Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma ( Dr Talal El Zarif - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer